Aerosol formulations containing P134a and particulate medicament
Patent 5922306 Issued on July 13, 1999. Estimated Expiration Date: 
April 15, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
April 15, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 2868691 2885427 3014844 3219533 3320125 3809294 3897779 Aerosol propellant compositions Composition for treating asthma Aerosol formulations containing P134a and particulate medicaments InventorsAssigneeApplicationNo. 060110 filed on 04/15/1998US Classes:424/45, Organic pressurized fluid424/46, Powder or dust containing514/826, ASTHMA514/937DISPERSION OR EMULSIONExaminersPrimary: Bawa, RajAttorney, Agent or FirmForeign Patent References
International ClassA61K 009/12Foreign Application Priority Data1991-12-12 GBAbstractA pharmaceutical formulation comprising (i) one or more particulate medicaments, and (ii) 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% w/w surfactant based upon the weight of medicament, particulate medicament being present in an amount from 0.005 to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof and with the proviso that when said formulation consists of betamethasone, ergotamine tartrate or sodium cromoglycate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866% w/w.Other References
| |
